In contrast, DRP-104, a DON peptide prodrug, is currently undergoing clinical trials and has been granted FDA Fast Track designation for the treatment of advanced non-small-cell lung cancer with KEAP1 (Kelch-like ECH-associated protein 1), NFE2L2 (Nuclear Factor, Erythroid 2 Like 2), and/or STK11 (Serine/Threonine Kinase 11) mutations in patients who have received prior therapy (NCT04471415). Here, NFE2L2 is linked to non-small cell lung carcinoma.